Skip to main content
Equibles
EDIT logo

EDIT · Editas Medicine, Inc.

Track EDIT — free

Use EDIT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about EDIT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.82 +0.01 (+0.36%) At close · Aug 14
Market Cap
$433.10M
Shares
153.58M

Editas Medicine, Inc. Earnings Call Transcripts

Every quarterly earnings call for Editas Medicine, Inc. (EDIT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1578.6% $6.36M −$53.45M '22 Q2 22-08-03 ▼99.3% $42,000 −$55.73M '22 Q3 22-11-02 ▼47.6% $6.54M −$60.74M '22 Q4 23-02-22 ▲45.5% $9.85M −$49.04M '23 Q1 23-05-05 ▼54.6% $2.89M −$40.29M '23 Q2 23-08-02 ▲12604.8% $5.34M −$45.02M '23 Q3 23-11-03 ▲818.6% $60.05M −$18.87M '23 Q4 24-02-28 ▼88.5% $1.14M −$61.95M '24 Q1 24-05-08 ▼82.2% $513,000 −$67.61M '24 Q2 24-08-07 ▼98.9% $61,000 −$62.14M '24 Q3 24-11-04 ▼49% $30.61M −$45.40M '24 Q4 25-01-13 ▲310.4% $4.66M −$76.09M '25 Q1 25-05-12 ▲597.5% $3.58M −$53.23M '25 Q2 25-09-02 ▲12265.6% $7.54M −$25.12M '25 Q3 25-11-10 ▼19.2% $24.74M −$5.62M '25 Q4 26-03-09 LATEST ▼39.2% $2.83M −$24.98M '26 Q1 26-05-05
Conference
Investor event
2026-06-04
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Editas Medicine, Inc. Q1 FY2026 Earnings Call
Revenue
$2.83M
▼ 39.2% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-12
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-09
Editas Medicine, Inc. Q4 FY2025 Earnings Call
Revenue
$24.74M*
▼ 19.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Editas Medicine, Inc. Q3 FY2025 Earnings Call
Revenue
$7.54M
▲ 12265.6% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-09-02
Editas Medicine, Inc. Q2 FY2025 Earnings Call
Revenue
$3.58M
▲ 597.5% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Editas Medicine, Inc. Q1 FY2025 Earnings Call
Revenue
$4.66M
▲ 310.4% YoY
Diluted EPS
$-0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Editas Medicine, Inc. Q4 FY2024 Earnings Call
Revenue
$30.61M*
▼ 49% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Editas Medicine, Inc. Q3 FY2024 Earnings Call
Revenue
$61,000
▼ 98.9% YoY
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Editas Medicine, Inc. Q2 FY2024 Earnings Call
Positive tone Reni-cel Clinical Progress (RUBY/EdiTHAL) In-Vivo Gene Editing Pipeline Enrollment and BLA Path
Revenue
$513,000
▼ 82.2% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Editas Medicine, Inc. Q1 FY2024 Earnings Call
Confident tone Reni-cel clinical progress and enrollment In vivo gene editing pipeline Regulatory and BLA pathway
Revenue
$1.14M
▼ 88.5% YoY
Diluted EPS
$-0.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Editas Medicine, Inc. Q4 FY2023 Earnings Call
Confident tone Reni-cel clinical development FDA regulatory alignment Enrollment and dosing progress
Revenue
$60.05M*
▲ 818.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Editas Medicine, Inc. Q3 FY2023 Earnings Call
Revenue
$5.34M
▲ 12604.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Editas Medicine, Inc. Q2 FY2023 Earnings Call
Revenue
$2.89M
▼ 54.6% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Editas Medicine, Inc. Q1 FY2023 Earnings Call
Revenue
$9.85M
▲ 45.5% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Editas Medicine, Inc. Q4 FY2022 Earnings Call
Revenue
$6.54M*
▼ 47.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Editas Medicine, Inc. Q3 FY2022 Earnings Call
Revenue
$42,000
▼ 99.3% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Editas Medicine, Inc. Q2 FY2022 Earnings Call
Revenue
$6.36M
▲ 1578.6% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Editas Medicine, Inc. Q1 FY2022 Earnings Call
Revenue
$6.77M
▲ 4.2% YoY
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Editas Medicine, Inc. Q4 FY2021 Earnings Call
Revenue
$12.47M*
▲ 9.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Editas Medicine, Inc. Q3 FY2021 Earnings Call
Revenue
$6.20M
▼ 90.1% YoY
Diluted EPS
$-0.57
▼ 575% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Editas Medicine, Inc. Q2 FY2021 Earnings Call
Revenue
$379,000
▼ 96.5% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Editas Medicine, Inc. Q1 FY2021 Earnings Call
Revenue
$6.50M
▲ 13.6% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
Editas Medicine, Inc. Q4 FY2020 Earnings Call
Revenue
$11.42M
▼ 7% YoY
Diluted EPS
$-1.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Editas Medicine, Inc. Q3 FY2020 Earnings Call
Revenue
$62.84M
▲ 1533.1% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Editas Medicine, Inc. Q2 FY2020 Earnings Call
Revenue
$10.75M
▲ 361.3% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Editas Medicine, Inc. Q1 FY2020 Earnings Call
Revenue
$5.72M
▲ 176.6% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Editas Medicine, Inc. Q4 FY2019 Earnings Call
Revenue
$12.28M
▲ 100.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 226 filings 201 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)